ATE220906T1 - Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen - Google Patents

Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen

Info

Publication number
ATE220906T1
ATE220906T1 AT96915500T AT96915500T ATE220906T1 AT E220906 T1 ATE220906 T1 AT E220906T1 AT 96915500 T AT96915500 T AT 96915500T AT 96915500 T AT96915500 T AT 96915500T AT E220906 T1 ATE220906 T1 AT E220906T1
Authority
AT
Austria
Prior art keywords
allergic
eye
treatment
formulation containing
topical
Prior art date
Application number
AT96915500T
Other languages
English (en)
Inventor
John Michael Yanni
Stella M Robertson
Eiji Hayakawa
Masashi Nakakura
Original Assignee
Alcon Lab Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23864859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE220906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Lab Inc, Kyowa Hakko Kogyo Kk filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE220906T1 publication Critical patent/ATE220906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96915500T 1995-06-06 1996-05-03 Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen ATE220906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,729 US5641805A (en) 1995-06-06 1995-06-06 Topical ophthalmic formulations for treating allergic eye diseases
PCT/US1996/006289 WO1996039147A2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases

Publications (1)

Publication Number Publication Date
ATE220906T1 true ATE220906T1 (de) 2002-08-15

Family

ID=23864859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915500T ATE220906T1 (de) 1995-06-06 1996-05-03 Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen

Country Status (20)

Country Link
US (1) US5641805A (de)
EP (1) EP0799044B1 (de)
JP (1) JP3068858B2 (de)
KR (1) KR100202155B1 (de)
CN (1) CN1082367C (de)
AT (1) ATE220906T1 (de)
AU (1) AU698854B2 (de)
CA (1) CA2195094C (de)
DE (2) DE69622527T2 (de)
DK (1) DK0799044T3 (de)
ES (1) ES2179198T3 (de)
FI (1) FI970489A7 (de)
LU (1) LU90969I2 (de)
MX (1) MX9701013A (de)
MY (1) MY116651A (de)
NL (1) NL300101I2 (de)
NO (1) NO311637B1 (de)
PT (1) PT799044E (de)
TW (1) TW438588B (de)
WO (1) WO1996039147A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
DE69900207T2 (de) * 1998-07-14 2001-11-22 Alcon Laboratories, Inc. Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
EP1187617B1 (de) 1999-06-18 2004-03-03 Alcon Manufacturing Ltd. Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung
US6375973B2 (en) 2000-01-25 2002-04-23 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses
JP2003534274A (ja) 2000-05-19 2003-11-18 アルコン，インコーポレイテッド アレルギー性疾患を処置するための、ベンズアミドジスルフィド誘導体を含む組成物
AU5722701A (en) 2000-05-19 2001-12-03 Alcon Universal Ltd Aniline disulfide derivatives for treating allergic diseases
DK1282599T3 (da) 2000-05-19 2006-07-31 Alcon Inc Disulfidderivater, der er egnede til behandling af allergiske sygdomme
US20040146502A1 (en) * 2001-05-03 2004-07-29 Elisabeth Latour Use of organic compounds
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
KR20050044550A (ko) * 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
BRPI0512732A (pt) * 2004-06-28 2008-04-08 Alcon Inc formulações tópicas para tratamento de doenças alérgicas
MX2007005845A (es) * 2004-11-24 2007-07-04 Alcon Inc Metodo para entregar rocio nasal.
ES2437077T3 (es) * 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
BRPI0710085B8 (pt) 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
PT2114367E (pt) 2007-02-07 2016-02-01 Novartis Ag Formulações de olopatadina para administração nasal tópica
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
WO2009031682A1 (ja) 2007-09-06 2009-03-12 Kyowa Hakko Kirin Co., Ltd. ジベンゾ[b,e]オキセピン誘導体含有点眼剤
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
PL2453872T3 (pl) 2009-07-17 2013-12-31 Alcon Res Ltd Olopatadyna w postaci spreju do donosowego podawania dzieciom
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103202833A (zh) * 2012-12-25 2013-07-17 常州市亚邦医药研究所有限公司 一种奥洛他定或其盐的药用组合物及其制备方法
WO2015065576A1 (en) * 2013-10-31 2015-05-07 Nephron Pharmaceuticals Corporation Formulation of olopatadine
CN113985041A (zh) * 2021-09-29 2022-01-28 武汉钢铁有限公司 一种实验室检测设备精度控制的控制限的设定方法及装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) * 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤

Also Published As

Publication number Publication date
DE69622527D1 (de) 2002-08-29
AU5726196A (en) 1996-12-24
NO311637B1 (no) 2001-12-27
JP3068858B2 (ja) 2000-07-24
WO1996039147A2 (en) 1996-12-12
EP0799044B1 (de) 2002-07-24
CN1161000A (zh) 1997-10-01
CA2195094A1 (en) 1996-12-12
JPH09510235A (ja) 1997-10-14
EP0799044A2 (de) 1997-10-08
DE10299034I2 (de) 2005-07-07
FI970489L (fi) 1997-02-05
FI970489A0 (fi) 1997-02-05
MY116651A (en) 2004-03-31
NL300101I2 (nl) 2003-01-06
LU90969I2 (fr) 2002-12-02
AU698854B2 (en) 1998-11-12
MX9701013A (es) 1997-05-31
NO970517L (no) 1997-04-03
FI970489A7 (fi) 1997-02-05
ES2179198T3 (es) 2003-01-16
CN1082367C (zh) 2002-04-10
DE10299034I1 (de) 2003-01-23
PT799044E (pt) 2002-11-29
KR100202155B1 (ko) 1999-06-15
NO970517D0 (no) 1997-02-05
TW438588B (en) 2001-06-07
DE69622527T2 (de) 2002-12-05
US5641805A (en) 1997-06-24
WO1996039147A3 (en) 1997-02-20
KR970704452A (ko) 1997-09-06
CA2195094C (en) 2002-02-26
NL300101I1 (nl) 2002-12-02
DK0799044T3 (da) 2002-10-14

Similar Documents

Publication Publication Date Title
ATE220906T1 (de) Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen
MA26901A1 (fr) Nouvelle composition pharmaceutique
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
ATE316779T1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69636167D1 (de) Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten
EP0842663A4 (de) Ophtalmika
ATE112960T1 (de) Anthocyanidine zur behandlung von augenkrankheiten.
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
IE870577L (en) Topical amide preparation
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks
RU95107870A (ru) Способ лечения послеоперационной цилиохориоидальной отслойки
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers